Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Pancreatic cancer is a highly lethal malignancy with limited treatment options.
• There is a critical need for novel therapeutic strategies to improve patient outcomes.

Purpose of the Study:

• To design and identify small-molecule inhibitors with dual activity against BET and HDAC proteins.
• To evaluate the therapeutic potential of these dual inhibitors in pancreatic cancer models.

Main Methods:

• Synthesis and characterization of novel small-molecule compounds.
• In vitro biochemical assays to determine inhibitory activity against BRD4 and HDAC1.
• In vitro and in vivo evaluation of anti-tumor efficacy compared to existing agents.

Main Results:

• A potent dual inhibitor (compound 13a) was identified with balanced activity against BRD4 BD1 (IC50 = 11 nM) and HDAC1 (IC50 = 21 nM).
• Compound 13a demonstrated superior in vitro and in vivo anti-tumor potency compared to single-target BET or HDAC inhibitors.
• The dual inhibition strategy showed enhanced efficacy over monotherapy or combination therapy with separate agents.

Conclusions:

• Simultaneous targeting of BET and HDAC proteins represents a promising therapeutic strategy for pancreatic cancer.
• The identified dual inhibitor (13a) exhibits significant anti-cancer potential and warrants further clinical investigation.
• BET/HDAC dual inhibitors offer advantages for more effective pancreatic cancer treatment.